Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beyond AirXAIR -2.58%23 Cash Ratio is 1.42 as of Jun. 2026, which is 57% below its 10-year median of 3.34. GuruFocus rates XAIR with a GF Score™ of 23/100 and a GF Value™ of $401.70 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Beyond Air ranks better than 60.32% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Beyond Air Cash Ratio Related Terms
Beyond Air Cash Ratio Historical Data
* Premium members only.
The historical data trend for Beyond Air's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Beyond Air's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Beyond Air's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air (XAIR) has a Cash Ratio of 1.42 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Beyond Air and its competitors. This is 57% below median its historical median of 3.34. Over the past decade, Beyond Air's Cash Ratio has ranged from 0.08 to 13.51. According to the industry distribution chart, Beyond Air ranks #319 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 39.7%.
Is Beyond Air's Cash Ratio too high?
Beyond Air's current Cash Ratio of 1.42 is 57% below median its 10-year median of 3.34. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 13.51. The Medical Devices & Instruments industry median Cash Ratio is 0.96. Beyond Air's value of 1.42 is 48.7% above this industry median. Based on the distribution chart, Beyond Air ranks #319 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Beyond Air has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's Cash Ratio compare to POAS and RMSL?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #319 out of 804 companies for Cash Ratio. This puts Beyond Air in the upper half of its industry. The industry median Cash Ratio is 0.96. Beyond Air's value of 1.42 is 48.7% above this benchmark. Historically, Beyond Air's own Cash Ratio has ranged from 0.08 to 13.51 over the past decade. While the company's 10-year median is 3.34 vs. the industry median of 0.96, Beyond Air has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.96, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beyond Air's current Cash Ratio of 1.42 is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Beyond Air and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beyond Air's current Cash Ratio is 1.42, which is 57% below median its own 10-year median of 3.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Based on GuruFocus' analysis, Beyond Air (XAIR) is currently considered Possible Value Trap. The stock's GF Value™ is $401.70, compared to a current price of $4.91 — trading 98.8% below its estimated fair value. The current Cash Ratio is 1.42, which is 57% below median its 10-year median of 3.34 and 48.7% above the Medical Devices & Instruments industry median of 0.96. Beyond Air's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Beyond Air (XAIR), the current Cash Ratio is 1.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beyond Air (XAIR) Overvalued in 2026?
Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued.
The current stock price of $4.91 is trading 98.8% below its estimated GF Value™ of $401.70.
GuruFocus considers Beyond Air to be Possible Value Trap.
Key valuation signals for XAIR:
Cash Ratio: 1.42 (57% below median its 10-year median of 3.34)
GF Value™: $401.70 vs. price of $4.91 (98.8% below fair value)
Industry Position: 48.7% above the Medical Devices & Instruments median (#319 of 804)
No single metric tells the full story. See the XAIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
23GF Score
Get the complete analysis for XAIR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAIR has been successfully added to your 
